El interés en corto de NewGenIvf Group da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de NewGenIvf Group. Los datos de interés en corto se actualizan cada dos semanas.

NewGenIvf Group (NASDAQ:NIVF) Bolsa, Informe de interés en corto

NewGenIvf Group

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group Ltd

Meta Platforms Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Instagram has the potential to generate 50% of the company&#8217;s advertising revenue in the U.S., Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-18/instagram-expected-to-generate-50-of-meta-s-us-ad-sales-in-2025?sref=TBDibEcD" rel="noreferrer noopener">cites</a> from Emarketer estimates.
Instagram could breach $32 billion in U.S. advertising revenue in 2025, up over 24% in 2024, as its short-form video product Reels gain traction, Bloomberg cites Emarketer. The video-sharing app boasts over 148 million American users.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42554393/disneys-marvel-rivals-game-hits-20-million-players-proves-superhero-power-still-reigns" rel="noreferrer noopener">Disney&#8217;s Marvel Rivals Game Hits 20 Million Players, Proves Superhero Power Still Reigns</a>
By early 2022, Instagram accounted for nearly 30%&nbsp;of Meta&#8217;s global business from 27% in 2021, Bloomberg cited court filings.
Reels competes with ByteDance&#8217;s TikTok and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube Shorts.
Meta&#8217;s focus on video content has been instrumental to its growth, as users devoted nearly 67% of their Instagram time to surfing videos, Bloomberg cited Jasmine Enberg of Emarketer.
<a target="_blank" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" rel="noreferrer noopener">The TikTok ban</a> could serve as a tailwind for Instagram, helping it win over 20% of reallocated TikTok ad dollars in the U.S, Reuters cites Enberg.
Meta previously told Instagram Reels accounted for over 50%&nbsp;of the time people spend on the app.
In 2024, 53.7% of Instagram&#8217;s ad revenue primarily came from its Feed features and 24.6% from Stories features. With Reels&#8217; revenue boost, the combined revenue share from Instagram Explore, Reels, and Threads could rise 9.6% in 2025.
In October, BofA Securities analyst Justin Post <a target="_blank" href="https://www.benzinga.com/news/24/10/41465662/metas-reels-monetization-and-ai-innovations-drive-top-ai-pick-analyst" rel="noreferrer noopener">projected Meta&#8217;s upside</a> from ramping up Messaging and Reel monetization powered by new artificial intelligence tools and CRM integration.
Meta Platforms stock surged 79% year-to-date. Investors can gain exposure to the stock through Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>) and The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>).
<h2 class="wp-block-heading">Is Meta A Good Stock To Buy?</h2>
An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. 
For example, for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), you'll notice that earnings in its last quarter grew 14.86% <a href="https://www.benzinga.com/quote/META/earnings">source</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio. 
On the valuation side, Meta Platforms's price to earnings ratio &#8211; a measure of how much an investor pays for the company's earnings &#8211; is compressed 15.56% in the current quarter when compared with last year. That places it below similar businesses Alphabet, Baidu, Pinterest in its sector. You'll need to decide whether that makes it more or less attractive based on how you think the company will perform over time.
There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/META">Meta Platforms's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.
Price Action: META stock is up 1.15% at $626.545 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42553094/jabil-q1-earnings-tops-expectations-cloud-and-data-center-growth-outlook" target="_blank" rel="noreferrer noopener">Jabil Q1 Earnings: Revenue And EPS Beat, Cloud and Data Center Growth, Raises Annual Outlook</a></li>
</ul>
Photo via Shutterstock

Tech

Media

GOOG

GOOGL

Instagram's Ad Revenue Could Hit $32 Billion by 2025, Driving Meta's Growth: Report

WIIM

AZTA

Azenta shares are trading higher after Stephens & Co. upgraded the stock to Overweight from Equal-Weight and raised its price target from $50 to $60.

Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock is trading higher on Wednesday after the company announced it secured a 400 MWh <a href="https://www.benzinga.com//node/42552632">standalone storage order</a> with International Electric Power.
The Details: This order is part of a project to be deployed at Marine Corps Base Camp Pendleton in San Diego, California which aims to enhance grid resiliency for the U.S. Navy and Marine Corps.
The project, supported by funding from the California Energy Commission's Long Duration Energy Storage Program, will use Eos Z3 batteries and is scheduled for delivery beginning in 2025. The Eos Z3 Cubes are safe, non-flammable and don't require cooling systems, which helps minimize noise and reduce operational costs.
&#8220;IEP and CEC are at the forefront of North American long-duration energy storage, and their partnership has been invaluable as Eos transitions into a profitable operating company. They recognize the need for multiple storage technologies and the energy security that an American-made product provides,&#8221; added Joe Mastrangelo, Eos CEO.
&#8220;It&#8217;s an honor to have been selected for such an important installation at Camp Pendleton.&#8221;
Related Link: <a href="https://www.benzinga.com/insights/options/24/12/42557838/palantir-technologies-unusual-options-activity">Palantir Technologies Unusual Options Activity</a>
EOSE Price Action: At the time of writing Eos Energy stock is trading 14.7% higher at $4.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Shutterstock

Movers

EOSE

What's Going On With Eos Energy Stock Wednesday?

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TH#TSX">TH</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) describing the changes made to the manufacturing environment of the facility where EGRIFTA SV&#xAE; is produced. A PAS is reviewed by the FDA within four months of receipt and an approval is needed prior to the distribution of the <a href="https://www.globenewswire.com/Tracker?data=8zHQ9qiyFO30h9BOfieWluYkNSdMsyvq24uHfuCufIVJuAcz2MC2Wi8JwO3uxPJK5Zg4Hnxe9yRK0YL8b-VwzIBT6sI1dIqefPxyrQH9SQcGs96Be7BtzwxdO12cw4ciN0DBUaDXb2Ey9HpTsYJ1aBwYpdHX5l1dgbBweAE30nUjyjJdJMuySCqOg_9-Q9R4FdrlVrl3X8KTmjgYmunrjBVx1NwAWJWd66efKQ6DFRo=">recently manufactured</a> batches of&nbsp;EGRIFTA SV&#xAE;.
Existing inventory levels of&nbsp;EGRIFTA SV&#xAE; are expected to meet patient demand until mid-January 2025. Theratechnologies therefore continues discussions with the relevant FDA divisions in an effort to accelerate the release of EGRIFTA SV&#xAE; and avoid a product shortage at the patient level.
The Company will update the market on any further material developments.
EGRIFTA SV&#xAE; is distributed in the United States only.

Biotech

General

THTX

TSX:TH

Theratechnologies Has Submitted A Prior Approval Supplement To The U.S. FDA Describing The Changes Made To The Manufacturing Environment Of The Facility Where EGRIFTA SV Is Produced

QBTS

D-Wave Quantum shares are trading higher amid continued volatility in quantum stocks.

<a href="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr" title="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr">https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr</a>

Contracts

PYPL

Reported Earlier, 'Bureau Secures $30M From Sorenson Capital, PayPal Ventures, Existing Investors' - Economic Times

In the current session, the stock is trading at $93.06, after a 0.44% spike. Over the past month, Lantheus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock increased by 7.65%, and in the past year, by 56.81%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_0.png" alt="Past Year Chart" />

<h3>Lantheus Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lantheus Holdings has a lower P/E than the aggregate P/E of 48.6 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

LNTH

P/E Ratio Insights for Lantheus Holdings

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 377%

Nukkleus Inc Shares Resume Trading

EGHT

8x8 shares are trading higher after Morgan Stanley raised its price target on the stock from $2 to $2.6.

Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) heads into its <a href="https://www.benzinga.com/quote/MU/earnings">first-quarter earnings</a> announcement with a mix of optimism and caution.
<h1 class="wp-block-heading">"Choppy Quarters Ahead"?</h1>
As Jake Silverman, Bloomberg Intelligence Semiconductor Analyst, puts it, "choppy quarters ahead for NAND" could pose a challenge, with pricing and inventory pressures in the smartphone and PC markets.
However, the analyst also highlights AI-related applications as a potential offset, giving Micron a chance to weather the storm.
Read Also: <a href="https://www.benzinga.com/24/12/42553082/how-to-earn-500-a-month-from-micron-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings</a>
<h1 class="wp-block-heading">Bullish Technical Signals Keep Optimists In The Game</h1>
Micron's stock, currently trading at $110.93, flashes bullish signs across key technical indicators. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png" alt="" class="wp-image-698134" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
It sits well above short- and medium-term moving averages, with the eight-day simple moving average (SMA) at $103.94, the 20-day SMA at $102.07 and the 50-day SMA at $104.07. 
The Moving Average Convergence Divergence (MACD) at 1.15 also suggests momentum is on the bulls' side.
However, the 200-day SMA of $110.93 coincides with the price, remaining a hurdle, signaling a potential resistance level.
<h1 class="wp-block-heading">AI: A Light At The End Of The NAND Tunnel?</h1>
The market will be laser-focused on how Micron balances the dynamics of two divergent forces:
<ol>
<li>NAND Weakness: Elevated inventories and pricing pressure.</li>
<li>AI Opportunities: As Silverman notes, secular growth in AI applications could provide a much-needed boost, potentially offsetting the broader NAND market challenges.</li>
</ol>
<h1 class="wp-block-heading">What's Expected?</h1>
Analysts estimate an EPS of $1.76 and revenue of $8.72 billion. But beyond these numbers, investors will be scrutinizing the company's guidance. Can Micron sustain its AI-driven growth momentum, or will "choppy quarters" in NAND drag it down?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/12/42549182/us-stocks-to-open-higher-as-rate-cut-expectations-surge-all-eyes-on-dow-jones-to-break-its-9-day-losing-streak">US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak</a></li>
</ul>
Photo: NPS_87 on Shutterstock

Technicals

Previews

Micron Earnings: Will AI Growth Outweigh 'Choppy' Memory Market?

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 319.6%

With Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices peaking to all-time high levels, MicroStrategy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) aggressive Bitcoin accumulation strategy has once again become a focal point in discussions among <a href="https://www.benzinga.com/markets/equities/24/12/42503221/microstrategy-shares-surge-nearly-7-amid-nasdaq-100-inclusion-and-bitcoins-new-record-high">traders and analysts</a>.
What Happened: In a tweet on Monday, industry expert Alex Kolicich addressed common misconceptions about MSTR in a recent tweet, explaining that the stock is neither a leveraged nor a synthetic call option on Bitcoin. 
Instead, Kolicich pointed out several structural inefficiencies:
<ul>
<li>MSTR trades at a 140% premium to its Bitcoin holdings&#8217; net asset value (NAV).</li>
<li>Each $1 invested in MSTR stock provides only $0.45 of Bitcoin exposure, far less than direct Bitcoin ownership.</li>
</ul>
Kolicich further <a href="https://x.com/AlexKolicich/status/1868705490387321177">elaborated</a> that MicroStrategy is not leveraged but instead deleveraged, offering reduced Bitcoin exposure compared to direct investments. 
He highlighted alternatives like BITX, which provide 2x leverage without a NAV premium.
Additionally, while traditional call options on assets typically offer leveraged upside due to their long volatility exposure, MSTR's convertible bonds effectively short volatility, diluting shareholder returns as Bitcoin prices rise.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42509614/microstrategy-expands-bitcoin-holdings-by-15350-btc-worth-15-billion-after-joining-nasdaq-100">MicroStrategy Expands Bitcoin Holdings By 15,350 BTC Worth $1.5 Billion After Joining Nasdaq 100</a>
Why It Matters: Crypto trader TheFlowHorse on Dec. 17 in a post on X emphasized the implications of Saylor&#8217;s aggressive Bitcoin purchases, noting that these acquisitions have significantly raised MicroStrategy's DCA to $61,000. 
This figure is approximately 40% higher than Bitcoin's current price, introducing potential risks if prices fail to recover significantly.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Take a look at Saylor&#39;s recent Bitcoin buys. The buys up here are so large that he has increased his dollar cost average price by nearly 50%, to 61k. That level is around 40% away. We haven&#39;t had a pullback of that magnitude for years, but at some point you have to wonder if in… <a href="https://t.co/erhdvrErn2">pic.twitter.com/erhdvrErn2</a>
&mdash; HORSE (@TheFlowHorse) <a href="https://twitter.com/TheFlowHorse/status/1868763016642052542?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Analysts warn that while Bitcoin&#8217;s pullbacks have historically been rare, Saylor's strategy could leave MSTR exposed to potential downside risk, especially with its C-Corp structure subject to double taxation, unlike <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42275232/leveraged-microstrategy-etfs-are-playing-with-fire-experts-warn">more efficient ETFs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42522606/trump-is-serious-about-creating-a-bitcoin-reserve-says-microstrategys-michael-saylorurges-to-buy-btc-before-it-goes-up-by-100x">Trump Serious About Bitcoin Reserve, Says MicroStrategy&#8217;s Michael Saylor: &#8216;Buy It Now And Own The Future&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy's Aggressive Bitcoin Strategy Raises Eyebrows In Crypto Community

Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42550503/corvus-pharmaceuticals-announces-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-so" rel="noreferrer noopener">severe atopic dermatitis</a>.&nbsp;
The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy.
These doses were selected based on the company&#8217;s prior experience evaluating soquelitinib in T-cell lymphoma patients.
The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.
The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to 18.5 and 3.3 for placebo patients.
EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo.
The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group.
<ul>
<li>At day 28, in the soquelitinib group, nine of 12 patients achieved EASI 50; three of 12 achieved EASI 75 and one of 12 achieved EASI 90. Three of the 12 patients achieved IGA 0 or 1. In the placebo group, two of four patients achieved EASI 50 and none achieved EASI 75, EASI 90, or IGA 0 or 1.</li>
<li>At day 58, in the soquelitinib group, nine of 10 patients achieved EASI 50, four of 10 achieved EASI 75 and one of 10 achieved EASI 90. Three of 10 patients achieved IGA 0 or 1. In the placebo group, one in four patients achieved EASI 50, and no patients achieved EASI 75, EASI 90, or IGA 0 or 1.</li>
</ul>
No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery.
Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42556198/united-microelectronics-signs-landmark-renewable-energy-deal-with-fengmiao-i-offshore-wind-farm-stock-gains" target="_blank" rel="noreferrer noopener">United Microelectronics Signs Landmark Renewable Energy Deal with Fengmiao I Offshore Wind Farm, Stock Gains</a></li>
</ul>

Health Care

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Toyota Motor shares are trading higher. The company announced it received funding from the US Department of Energy for the development of EV battery life cycles.

NVDA

NVIDIA shares are trading higher amid overall market strength ahead of the Fed's decision. Additionally, Omdia estimated that Microsoft bought 485,000 of Nvidia's Hopper chips this year.

PLTR

Palantir Technologies shares are trading higher after the company joined forces with Pray.com to enhance multilingual faith-based content using advanced AI technology.

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares are trading lower Wednesday, pulling back from a recent surge that saw the stock join the $1 trillion club. Here&#8217;s a look at what <a href="https://www.benzinga.com/24/12/42536512/market-breadth-worsens-as-tech-giants-break-free-from-sp-500-reality-is-this-bullish-or-bearish-for-2025">you need to know</a>.
What To Know: Broadcom shares have been on a tear over the past week, gaining nearly 40% since <a href="https://www.benzinga.com/news/earnings/24/12/42472970/broadcom-reports-mixed-q4-results-eps-beat-revenues-miss-q1-guidance-in-line-with-estimates">reporting earnings</a>. Broadcom shares soared after the company beat earnings estimates and provided strong guidance for AI-related revenue growth.
Broadcom&#8217;s fourth-quarter revenue was up 51% year-over-year to $14.05 billion, but came up short of estimates of $14.09 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Despite the miss on overall revenue, Broadcom reported a 220% increase in AI revenue and guided for significant growth in 2025. Positive commentary surrounding AI on the call also helped drive momentum to the upside.
Broadcom CEO Hock Tan said on the call with analysts and investors that he expects the total addressable market for the company&#8217;s AI chips to be between $60 billion and $90 billion over the next few years. He also announced that the company was working on custom AI chips with large cloud customers, <a href="https://www.cnbc.com/2024/12/13/broadcom-stock-jumps-21percent-pushing-company-past-1-trillion-market-cap-for-the-first-time.html">per</a> CNBC.
Reports from last week suggested that Broadcom was working with Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) on <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42439155/broadcom-stock-jumps-on-apple-ai-chip-report-whats-going-on">AI chip development</a>. The company is reportedly working on development of an AI server chip&#8217;s networking technology. Broadcom shares got a boost from the news. 
Several analysts have weighed in with positive updates since the company reported fourth-quarter results. Multiple analysts maintained Overweight ratings, while others kept Buy ratings on the name. Newly-issued price targets range from $205 to $255. 
The weakness in Broadcom shares on Wednesday appears to be due to profit-taking in the wake of Broadcom&#8217;s incredible surge above the $1 trillion market cap mark. Broadcom shares hit new all-time highs this week, so the stock is likely to remain volatile as investors try to determine the appropriate value of the stock given the recent string of AI news.
It&#8217;s worth noting that Broadcom was among the top trending stocks on Reddit&#8217;s WallStreetBets on Wednesday, suggesting retail investors are also sizing up the name.
Check This Out: <a href="https://www.benzinga.com/24/12/42531167/broadcom-dethrones-nvidia-as-ais-new-darling-valuation-multiple-suggests-ai-momentum-shift">Broadcom Outpaces Nvidia In AI Chip Stock Valuation Race: Is Investor Sentiment Shifting?</a>
AVGO Price Action: <a href="http://benzinga.com/quote/avgo">Broadcom shares</a> were down 3.33% at $232.18 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

AAPL

AVGO

What's Going On With Broadcom Stock?

KULR Technology Group, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) shares are trading higher on Wednesday after the company announced it regained NYSE stockholder&#8217;s equity required compliance status. Here&#8217;s what you <a href="https://www.benzinga.com/24/12/42559178/worthington-enterprises-posts-upbeat-results-joins-jabil-archer-aviation-and-other-big-stocks-moving-higher-on-wednesday">need to know</a>.
What To Know: The company was previously cited for non-compliance with Sections 1003(a)(i), (ii) and (iii) of Part 10 of the NYSE American Company Guide in December 2023.
KULR has since demonstrated compliance with these standards for two consecutive quarters. Given the company&#8217;s compliance, the company has been removed from NYSE American noncompliant issuers on the exchange&#8217;s website.
How To Buy KULR Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in KULR Tech Gr's case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/24/12/42558554/abm-industries-earnings-beat-expectations-but-shares-slide-on-profit-decline">ABM Industries Stumbles Despite Q4 Earnings Beat &#8211; What&#8217;s Going On?</a>
KULR Price Action: At the time of writing, KULR shares are 76% higher at $2.57, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Shutterstock

KULR

What's Going On With KULR Technology Stock Wednesday?

Broadcom shares are trading lower, pulling back from its recent post-earnings surge.

NOTV, BFRI and CPOP among pre-market losers

SPWR, BIG and BOLT among pre-market losers

NewGenIvf receives Nasdaq non-compliance notifications

NewGenIvf updates on potential reverse merger with COVIRIX

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

NewGenIvf surges after binding term sheet news with White Lion for $100M equity line of credit

NewGenIvf Group (NIVF) has entered into a binding term sheet with White Lion Capital, setting out the principal terms and conditions for a $100 mil...

NewGenIvf Group enters binding term sheet with White Lion Capital

NewGenIvf gets delisting notice from Nasdaq

NewGenIvf Group (NIVF) announced that on November 21 2024, it received written notice from The Nasdaq Stock Market that its securities are subject ...

NewGenIvf Group receives Nasdaq delisting notice, plans to appeal

NewGenIvf Group (NIVF) has entered into a binding term sheet regarding the previously announced proposed reverse merger with healthcare company Eur...

NewGenIvf Group announces proposed reverse merger with EWIHL

ACIU

ALLR

ATCH

ATIP

ATPC

AZTR

BBLG

BFRI

BOLT

CJET

CONN

CPOP

CTNT

DRMA

HOLO

HOTH

KOSS

NOTV

NUZE

OKLO

PIRS

PMNT

RYDE

SAGE

SLRX

SOAR

SPWR

VRPX

VSTM

VTAK

The Search Is Over: NewGenIVF Inks Reverse Merger Agreement With European Wellness Investment Holdings

Press Releases

NewGenIvf Provides Update on Potential Reverse Merger with COVIRIX

NewGenIvf Announces Filing of 2023 Annual Report with the SEC

NewGenIvf Receives Nasdaq Notification Regarding Minimum Bid Price

Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Financing

NewGenIvf Enters into a Binding Term Sheet with White Lion Capital for $100 Million Equity Line of Credit, Expandable to $500 Million

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

NewGenIvf Receives Nasdaq Delisting Notice and Plans to Submit Appeal, Announces Strategic Path Forward to Regain Compliance

NewGen Signs Binding Term Sheet for Reverse Merger with European Wellness Investment Holdings

AGBA

APLM

BNZI

BREA

CRDL

DRUG

HCWB

ILLR

NIXX

PRSO

RANI

SINT

STAF

TVGN

VMAR

VSME

XPON

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Vivos Therapeutics

Comments

NewGenIvf Group

Interés en corto

NewGenIvf Group (NASDAQ:NIVF) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL